Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
905.38
-3.66 (-0.40%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
85
86
Next >
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
December 04, 2023
This dividend-paying pharma stock is on a roll.
Via
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
FDA Grants Second Conditional Approval For Eli Lilly's Rare Blood Cancer Drug
December 04, 2023
Friday, the FDA approved Eli Lilly and Co's (NYSE: LLY) Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymp
Via
Benzinga
Exposures
Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
December 04, 2023
Roche Holding AG (OTC: RHHBY) has agreed to
Via
Benzinga
3 No-Brainer Growth Stocks to Buy in December
December 03, 2023
No analysis paralysis is required with these great stocks.
Via
The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,200 Today
December 01, 2023
Via
Benzinga
Eli Lilly's Options: A Look at What the Big Money is Thinking
November 28, 2023
Via
Benzinga
Elliott Wave Technical Analysis: Eli Lilly & Co.
November 28, 2023
Looking for a triangle in wave (b) as we seem to be near the end of the correction.
Via
Talk Markets
Pfizer Tumbles After Abandoning Weight-Loss Pill
December 02, 2023
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate...
Via
Talk Markets
An Important History Lesson for Gene-Editing Investors
December 02, 2023
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
Via
The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
December 02, 2023
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.
Via
The Motley Fool
5 Top Stocks to Buy Before 2024
December 02, 2023
These stocks have room to run -- next year and over the long term.
Via
The Motley Fool
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...
Via
Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
December 01, 2023
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO).
Via
Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
December 01, 2023
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell.
Via
Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
December 01, 2023
Software earnings were strong, while the Fed is shifting toward rate cuts.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
December 01, 2023
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug.
Via
Talk Markets
1 Underrated Reason to Buy Eli Lilly Stock
December 01, 2023
Eli Lilly has a well-rounded business that can be a good fit for all types of investors.
Via
The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
November 30, 2023
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
November 30, 2023
Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.
Via
The Motley Fool
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
November 29, 2023
Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's (NYSE: NVO)
Via
Benzinga
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
November 29, 2023
Real-world data showed some real-world advantages for Ozempic's top rival.
Via
The Motley Fool
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
November 28, 2023
The study examined health care records for more than 41,000 people.
Via
Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
November 28, 2023
A recent extensive analysis by Truveta Research has
Via
Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
November 27, 2023
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.
Via
Talk Markets
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
November 27, 2023
Novo Nordisk A/S (NYSE: NVO) is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight
Via
Benzinga
3 Top Stocks That'll Make Smart Investors Rich
November 27, 2023
Long-term investing is one possible path to riches.
Via
The Motley Fool
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
November 26, 2023
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.
Via
The Motley Fool
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
November 26, 2023
There's no time like the present to buy these stocks.
Via
The Motley Fool
Google Leads Five S&P 500 Stocks Near Buy Points
November 25, 2023
Four of the stocks tripped up after earnings, but quickly bounced back.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
85
86
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.